Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects

What Was Tested

The paper reports a study of Ghrelin, published as a randomized controlled trial.

Ghrelin is a gut-brain peptide that powerfully stimulates appetite and growth hormone secretion and is also known to directly regulate osteoblast cell function in vitro and in animal models.

Little is known about the effects of ghrelin on bone turnover in humans.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Subjects were given a fixed energy meal during the infusion.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Ghrelin.

A placebo (an inactive look-alike) gave the Ghrelin group a baseline to be compared against.

Ghrelin, GH, type-1 collagen beta C-telopeptide (betaCTX), a marker of bone resorption, and procollagen type-1 amino-terminal propeptide (P1NP), a marker of bone formation, were measured.

What Was Measured

PubMed files the paper under topics including Bone Remodeling, Collagen Type I, Gastrectomy, Ghrelin, Human Growth Hormone, Peptide Fragments and Peptide Hormones.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (Bone), a journal based in United States.

More context: the Ghrelin compound page, all human trials.